PMID- 20304104
OWN - NLM
STAT- MEDLINE
DCOM- 20100903
LR  - 20131121
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 10
IP  - 6
DP  - 2010 Jun
TI  - Effect of 5-aminosalicylate on allergic rhinitis model in mice.
PG  - 713-6
LID - 10.1016/j.intimp.2010.03.007 [doi]
AB  - Previous studies have shown that peroxisome proliferator-activated receptor gamma 
      (PPARgamma) is involved in allergic rhinitis. It has been reported that 
      5-aminosalicylate (5-ASA) has an affinity for PPARgamma, but the effects of 5-ASA 
      on the nasal symptoms of allergic rhinitis are unclear. This study aimed to 
      clarify the effects of 5-ASA on nasal symptoms in an allergic rhinitis model in 
      mice. Female BALB/c mice were sensitized by intraperitoneal injection of 
      ovalbumin (OVA) and aluminium hydroxide hydrate gel (alum) on days 0, 5, 14 and 
      21. Seven days later, mice were sensitized by the intranasal application of OVA 
      thrice a week. 5-ASA was also administered orally after instillation of the 
      antigen from day 28. The severity of allergic rhinitis was assessed by 
      determining the extent of 2 nasal allergic symptoms-sneezing and nasal rubbing. 
      In addition, serum OVA-specific immunoglobulin E (IgE) antibody, interleukin 
      (IL)-4, and IL-10 levels in nasal lavage fluid and histamine sensitivity were 
      determined. Repeated oral administration of 5-ASA attenuated the progression of 
      nasal symptoms in sensitized mice in a dose-dependent manner. Additionally, 5-ASA 
      prevented an increase in histamine sensitivity. Finally, 5-ASA inhibited both 
      OVA-specific IgE antibody and IL-4 production; however, it had no effect on IL-10 
      levels. These results indicate that 5-ASA has a prophylactic effect on allergic 
      rhinitis.
CI  - Copyright 2010 Elsevier B.V. All rights reserved.
FAU - Kuyama, Shoji
AU  - Kuyama S
AD  - Department of Medicinal Pharmacology, Okayama University Graduate School of 
      Medicine, Dentistry and Pharmaceutical Sciences, Tsushima-naka 1-1-1, Okayama 
      700-8530, Japan.
FAU - Yamamoto, Atsuki
AU  - Yamamoto A
FAU - Sugiyama, Mayu
AU  - Sugiyama M
FAU - Kakuta, Hiroki
AU  - Kakuta H
FAU - Sugimoto, Yukio
AU  - Sugimoto Y
LA  - eng
PT  - Journal Article
DEP - 20100319
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (PPAR gamma)
RN  - 130068-27-8 (Interleukin-10)
RN  - 207137-56-2 (Interleukin-4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 4Q81I59GXC (Mesalamine)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
RN  - 820484N8I3 (Histamine)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Aluminum Hydroxide/immunology
MH  - Animals
MH  - Anti-Allergic Agents/*therapeutic use
MH  - Female
MH  - Histamine/pharmacology
MH  - Immunoglobulin E/blood
MH  - Interleukin-10/analysis/immunology
MH  - Interleukin-4/analysis/immunology
MH  - Mesalamine/*therapeutic use
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Nasal Lavage Fluid/chemistry/immunology
MH  - Ovalbumin/immunology
MH  - PPAR gamma/*agonists
MH  - Rhinitis, Allergic, Perennial/*prevention & control
MH  - Sneezing/drug effects/immunology
EDAT- 2010/03/23 06:00
MHDA- 2010/09/04 06:00
CRDT- 2010/03/23 06:00
PHST- 2009/12/25 00:00 [received]
PHST- 2010/02/27 00:00 [revised]
PHST- 2010/03/12 00:00 [accepted]
PHST- 2010/03/23 06:00 [entrez]
PHST- 2010/03/23 06:00 [pubmed]
PHST- 2010/09/04 06:00 [medline]
AID - S1567-5769(10)00091-3 [pii]
AID - 10.1016/j.intimp.2010.03.007 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2010 Jun;10(6):713-6. doi: 10.1016/j.intimp.2010.03.007. 
      Epub 2010 Mar 19.